Gerrit J Braunstahl

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1279029/publications.pdf

Version: 2024-02-01

147566 133063 3,677 98 31 59 citations g-index h-index papers 103 103 103 4122 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Voice bubbling therapy for vocal cord dysfunction in difficult-to-treat asthma – a pilot study. Journal of Asthma, 2022, 59, 200-205.	0.9	2
2	Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma. Clinical Respiratory Journal, 2022, , .	0.6	6
3	Alpine altitude climate treatment for severe and uncontrolled asthma: An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1991-2024.	2.7	21
4	STOP: an open label crossover trial to study ICS withdrawal in patients with a combination of obesity and low-inflammatory asthma and evaluate its effect on asthma control and quality of life. BMC Pulmonary Medicine, 2022, 22, 53.	0.8	1
5	Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands – An evaluation. Respiratory Medicine, 2022, 194, 106776.	1.3	1
6	The effect of the COVID-19 pandemic on severe asthma care in Europe - will care change for good?. ERJ Open Research, 2022, 8, 00065-2022.	1.1	3
7	Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety. Journal of Asthma, 2021, 58, 651-658.	0.9	26
8	Steroid-resistant human inflammatory ILC2s are marked by CD45RO and elevated in type 2 respiratory diseases. Science Immunology, 2021, 6, .	5.6	65
9	Asthma patients experience increased symptoms of anxiety, depression and fear during the COVID-19 pandemic. Chronic Respiratory Disease, 2021, 18, 147997312110296.	1.0	16
10	Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy. Respiratory Medicine, 2021, 177, 106287.	1.3	45
11	The impact of the involvement of a healthcare professional on the usage of an eHealth platform: a retrospective observational COPD study. Respiratory Research, 2021, 22, 88.	1.4	12
12	Incidence and predictors of asthma exacerbations in middle-aged and older adults: the Rotterdam Study. ERJ Open Research, 2021, 7, 00126-2021.	1.1	1
13	Association between elevated serum triglycerides and asthma in patients with obesity: An explorative study. Allergy and Asthma Proceedings, 2021, 42, e71-e76.	1.0	8
14	Asthma exacerbation prevalence during the COVID-19 lockdown in a moderate-severe asthma cohort. BMJ Open Respiratory Research, 2021, 8, e000758.	1.2	31
15	Pneumomediastinum in a patient with COVID-19 due to diffuse alveolar damage. BMJ Case Reports, 2021, 14, e242527.	0.2	4
16	Bacterial lysate addâ€on therapy to reduce exacerbations in severe asthma: A doubleâ€blind placeboâ€controlled trial. Clinical and Experimental Allergy, 2021, 51, 1172-1184.	1.4	9
17	Imatinib in patients with severe COVID-19: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Respiratory Medicine,the, 2021, 9, 957-968.	5. 2	83
18	Adult but not childhood onset asthma is associated with the metabolic syndrome, independent from body mass index. Respiratory Medicine, 2021, 188, 106603.	1.3	14

#	Article	IF	Citations
19	Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19., 2021,,.		O
20	Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab. Clinical and Translational Allergy, 2021, 11, e12081.	1.4	8
21	Roadmap to improve regional care for patients with severe asthma. Clinical and Translational Allergy, 2021, 11, e12080.	1.4	1
22	A meta-analysis of baseline characteristics in trials on mite allergen avoidance in asthmatics: room for improvement. Clinical and Translational Allergy, 2020, 10, 2.	1.4	13
23	Describing fluctuating indoor aerosol dust measurements with application to house dust mite allergens. Scientific Reports, 2020, 10, 16897.	1.6	2
24	Bacterial lysate therapy for the prevention of wheezing episodes and asthma exacerbations: a systematic review and meta-analysis. European Respiratory Review, 2020, 29, 190175.	3.0	31
25	Analyses of abdominal adiposity and metabolic syndrome as risk factors for respiratory distress in COVID-19. BMJ Open Respiratory Research, 2020, 7, e000792.	1.2	23
26	Pneumothorax in patients with prior or current COVID-19 pneumonia. Respiratory Medicine Case Reports, 2020, 31, 101187.	0.2	28
27	Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2999-3008.e1.	2.0	17
28	Effectiveness of the Air Purification Strategies for the Treatment of Allergic Asthma: A Meta-Analysis. International Archives of Allergy and Immunology, 2020, 181, 395-402.	0.9	6
29	Short-term and long-term effect of a high-intensity pulmonary rehabilitation programme in obese patients with asthma: a randomised controlled trial. European Respiratory Journal, 2020, 56, 1901820.	3.1	29
30	Type II conventional dendritic cells of asthmatic patients with frequent exacerbations have an altered phenotype and frequency. European Respiratory Journal, 2020, 55, 1900859.	3.1	2
31	Characteristics and treatment regimens across ERS SHARP severe asthma registries. European Respiratory Journal, 2020, 55, 1901163.	3.1	56
32	Uncontrolled asthma has a higher disease burden compared to controlled asthma in adult onset but not in childhood onset asthma. , 2020, , .		0
33	Obesity and asthma: very long-term effect of bariatric surgery on lung function and asthma control. , 2020, , .		0
34	Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD. , 2020, , .		1
35	A reintroduction of environmental mite allergen control strategies for asthma treatment and the debate on their effectiveness. Clinical and Experimental Allergy, 2019, 49, 400-409.	1.4	14
36	Increased eosinophil uptake in the lungs of obese patients with asthmaâ€"to correct for obesity compared to obese controls. Journal of Allergy and Clinical Immunology, 2019, 143, 1265.	1.5	1

#	Article	lF	Citations
37	Prediction of Airflow Obstruction and the Risk of Complications in Morbidly Obese Patients Undergoing Bariatric Surgery. Obesity Surgery, 2019, 29, 3076-3080.	1.1	1
38	Increased surface expression of NOTCH on memory T cells in peripheral blood from patients with asthma. Journal of Allergy and Clinical Immunology, 2019, 143, 769-771.e3.	1.5	17
39	Characteristics and treatment regimens across ERS SHARP severe asthma registries. , 2019, , .		3
40	Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice., 2019,,.		0
41	Asthma and its comorbidities in middle-aged and older adults; the Rotterdam Study. Respiratory Medicine, 2018, 139, 6-12.	1.3	32
42	Discrepancies Between BMI and Classic Cardiovascular Risk Factors. Obesity Surgery, 2018, 28, 3484-3491.	1.1	8
43	A pathophysiological role of PDE3 in allergic airway inflammation. JCI Insight, 2018, 3, .	2.3	33
44	Bacterial lysates in the prevention of asthma exacerbations in uncontrolled asthma: the Breathe study. , 2018 , , .		2
45	Prediction of obstructive lung function and the risk of complications in morbidly obese patients undergoing bariatric surgery. , $2018, , .$		0
46	Long-term effects of a high intensity life style program in obese patients with asthma. , 2018, , .		0
47	Relations between serum lipid levels and inflammatory markers in obese asthma, 2018,,.		0
48	Effect of an Outpatient Pulmonary Rehabilitation Program on Exercise Tolerance and Asthma Control in Obese Asthma Patients. Journal of Cardiopulmonary Rehabilitation and Prevention, 2017, 37, 214-222.	1.2	16
49	Pre-surgical Pulmonary Rehabilitation in Asthma Patients Undergoing Bariatric Surgery. Obesity Surgery, 2017, 27, 3055-3060.	1.1	9
50	Associations Between Systemic and Local Corticosteroid Use With Metabolic Syndrome and Body Mass Index. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3765-3774.	1.8	28
51	4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry. Allergy, Asthma and Clinical Immunology, 2017, 13, 34.	0.9	9
52	High intensity training in obesity: a Meta-analysis. Obesity Science and Practice, 2017, 3, 258-271.	1.0	84
53	Mepolizumab improves activity limitation in severe eosinophilic asthma., 2017,,.		0
54	Characterization of adipose tissue inflammation in morbidly obese asthmatics., 2017,,.		0

#	Article	IF	Citations
55	Effect of a high intensity life style program on asthma control in obese patients with asthma. , 2017, , .		1
56	Regulation of melanocortin 1 receptor in allergic rhinitis <i>in vitro</i> and <i>in vivo</i> . Clinical and Experimental Allergy, 2016, 46, 1066-1074.	1.4	9
57	The Dutch National Program for Respiratory Research. Lancet Respiratory Medicine, the, 2016, 4, 356-357.	5.2	5
58	Evaluation of new laboratory tests to discriminate bacterial from nonbacterial chronic obstructive pulmonary disease exacerbations. International Journal of Laboratory Hematology, 2016, 38, 616-628.	0.7	15
59	Targeted Therapy for Older Patients with Uncontrolled Severe Asthma: Current and Future Prospects. Drugs and Aging, 2016, 33, 619-628.	1.3	5
60	Decreased physical activity in adults with bronchial asthma. Respiratory Medicine, 2016, 114, 72-77.	1.3	50
61	<i>In vivo</i> diagnosis of allergic diseases-allergen provocation tests. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 355-365.	2.7	81
62	Development of an integral assessment approach of health status in patients with obstructive airway diseases: the CORONA study. International Journal of COPD, 2015, 10, 2413.	0.9	18
63	Discrepancies in the relationship of BMI and traditional cardiovascular risk factors in subjects with different levels of obesity. Surgery for Obesity and Related Diseases, 2015, 11, S75-S76.	1.0	0
64	Effect of bariatric surgery on asthma control, lung function and bronchial and systemic inflammation in morbidly obese subjects with asthma. Thorax, 2015, 70, 659-667.	2.7	147
65	The effect of an outpatient pulmonary rehabilitation program on exercise tolerance and asthma control in obese asthma patients. , $2015, \ldots$		0
66	Healthcare Resource Utilization in Patients Receiving Omalizumab for Allergic Asthma in a Real-World Setting. Biologics in Therapy, 2014, 4, 57-67.	1.8	18
67	Bronchial and Systemic Inflammation in Morbidly Obese Subjects with Asthma: A Biopsy Study. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 951-954.	2.5	29
68	Healthcare utilization and indirect cost of treatment associated with severe allergic asthma in a realâ€world setting. Clinical and Translational Allergy, 2013, 3, P1.	1.4	1
69	Reduction in oral corticosteroid use in patients with severe allergic (IgEâ€mediated) asthma receiving omalizumab in a realâ€world setting. Clinical and Translational Allergy, 2013, 3, P13.	1.4	4
70	Pulmonary Function Testing and Complications of Laparoscopic Bariatric Surgery. Obesity Surgery, 2013, 23, 1596-1603.	1.1	42
71	Underdiagnosis and overdiagnosis of asthma in the morbidly obese. Respiratory Medicine, 2013, 107, 1356-1364.	1.3	48
72	The eXpeRience registry: The â€~real-world' effectiveness of omalizumab in allergic asthma. Respiratory Medicine, 2013, 107, 1141-1151.	1.3	169

#	Article	IF	CITATIONS
73	Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy, Asthma and Clinical Immunology, 2013, 9, 47.	0.9	54
74	Stepping-across controlled asthmatic patients to extrafine beclometasone/formoterol combination. Pulmonary Pharmacology and Therapeutics, 2013, 26, 555-561.	1.1	16
75	Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. Journal of Medical Economics, 2013, 16, 342-348.	1.0	43
76	Systemic Inflammation and Lung Function Impairment in Morbidly Obese Subjects with the Metabolic Syndrome. Journal of Obesity, 2013, 2013, 1-8.	1.1	40
77	Reductions In Oral Corticosteroid Use In Patients With Allergic (IgE- Mediated) Asthma Receiving Omalizumab. Journal of Allergy and Clinical Immunology, 2012, 129, AB72.	1.5	0
78	Utility of nitric oxide for the diagnosis of asthma in an allergy clinic population. Allergy and Asthma Proceedings, 2011, 32, 119-126.	1.0	29
79	Chronic rhinosinusitis, nasal polyposis and asthma: the united airways concept reconsidered?. Clinical and Experimental Allergy, 2011, 41, 1341-1343.	1.4	7
80	Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics. Current Medical Research and Opinion, 2011, 27, 761-767.	0.9	16
81	Internet-based tapering of oral corticosteroids in severe asthma: a pragmatic randomised controlled trial. Thorax, 2011, 66, 514-520.	2.7	54
82	The role of neurotrophins in the pathophysiology of allergic rhinitis. Current Opinion in Allergy and Clinical Immunology, 2010, 10, 8-13.	1.1	56
83	Sarcoidosis During Anti-Tumor Necrosis Factor-α Therapy: No Relapse After Rechallenge. Journal of Rheumatology, 2009, 36, 2847-2848.	1.0	33
84	United Airways Concept: What Does it Teach Us about Systemic Inflammation in Airways Disease?. Proceedings of the American Thoracic Society, 2009, 6, 652-654.	3.5	68
85	Modulation of neurotrophin and neurotrophin receptor expression in nasal mucosa after nasal allergen provocation in allergic rhinitis. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 468-475.	2.7	51
86	Altered expression of epithelial junctional proteins in atopic asthma: possible role in inflammation. Canadian Journal of Physiology and Pharmacology, 2008, 86, 105-112.	0.7	198
87	An essential role for dendritic cells in human and experimental allergic rhinitis. Journal of Allergy and Clinical Immunology, 2006, 118, 1117-1125.	1.5	104
88	Nasobronchial interaction mechanisms in allergic airways disease. Current Opinion in Otolaryngology and Head and Neck Surgery, 2006, 14, 176-182.	0.8	38
89	Postgraduate Course ERS Copenhagen 2005: Biological and therapeutic implications of the united airways concept. Breathe, 2006, 2, 231-235.	0.6	0
90	Desloratadine reduces systemic allergic inflammation following nasal provocation in allergic rhinitis and asthma patients. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 1301-1307.	2.7	33

#	Article	IF	CITATIONS
91	The unified immune system: Respiratory tract–nasobronchial interaction mechanisms in allergic airway disease. Journal of Allergy and Clinical Immunology, 2005, 115, 142-148.	1.5	100
92	Nasal involvement in allergic asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2003, 58, 1235-1243.	2.7	94
93	Mucosal and systemic inflammatory changes in allergic rhinitis and asthma: a comparison between upper and lower airways. Clinical and Experimental Allergy, 2003, 33, 579-587.	1.4	158
94	Allergic rhinitis and asthma: the link further unraveled. Current Opinion in Pulmonary Medicine, 2003, 9, 46-51.	1.2	54
95	Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. Journal of Allergy and Clinical Immunology, 2001, 107, 469-476.	1.5	411
96	Segmental Bronchoprovocation in Allergic Rhinitis Patients Affects Mast Cell and Basophil Numbers in Nasal and Bronchial Mucosa. American Journal of Respiratory and Critical Care Medicine, 2001, 164, 858-865.	2.5	185
97	Segmental Bronchial Provocation Induces Nasal Inflammation in Allergic Rhinitis Patients. American Journal of Respiratory and Critical Care Medicine, 2000, 161, 2051-2057.	2.5	367
98	Antibiotic Prescriptions in Hospitalized Patients with an Exacerbation COPD and a Proven Influenza or RS Virus Infection. International Journal of COPD, 0, Volume 17, 1261-1267.	0.9	1